PDI, Inc. Appoints Molecular Diagnostics Leader to Board of Directors

    PDI, Inc. Appoints Molecular Diagnostics Leader to Board of Directors

PR Newswire

PARSIPPANY, N.J., Oct. 30, 2013

PARSIPPANY, N.J., Oct. 30, 2013 /PRNewswire/ -- PDI, Inc. (Nasdaq: PDII) today
announced that it has appointed molecular diagnostics industry veteran John M.
Climaco, J.D., to its board of directors, bringing the board to seven members.

"As we continue to execute on our strategic vision of solidifying a position
in the molecular diagnostics space, we welcome John's unparalleled business
expertise in this market," said Nancy Lurker, chief executive officer of PDI,
Inc. "John's role will be invaluable to the board as we continue to expand our
footprint in this arena."

Mr. Climaco co-founded Axial Biotech, Inc., a venture-backed molecular
diagnostics company specializing in spine disorders, in 2003, and served as
the president, chief executive officer and board member until 2012. Under Mr.
Climaco's leadership, the company partnered with companies including
Medtronic, Johnson & Johnson and Smith & Nephew to successfully develop and
commercialize ScoliScore™, the first molecular prognostic test in the
orthopedic industry. Among other accolades, Orthopaedics This Week magazine
recognized ScoliScore as the Best New Diagnostics Technology for Spine Care
2010, and the Utah Technology Council named ScoliScore as the 2009 Utah
Innovation Award winner in biotechnology. In addition, ScoliScore and its
benefits to patients have been featured in The New York Times, Chicago Tribune
and on MSNBC, CNBC and many other media outlets.

Mr. Climaco currently serves as a director on the boards of DigiRad
Corporationand Perma-Fix Environmental Services, Inc. Previously, he
practiced corporate and tax law for six years with Fabian & Clendenin in Salt
Lake City. Earlier, he held the role of director of programming for Quokka
Sports, a venture-backed online media company that went public in 1999. While
with Quokka, Mr. Climaco helped to create and manage partnerships with Intel,
Microsoft WebTV, NBC Sports and National Geographic. Mr. Climaco holds a
Bachelor of Arts in philosophy, cum laude, from Middlebury College and a Juris
Doctorate from the University of California, Hastings College of Law.

"I'm honored to join PDI's board at such a pivotal time in the company's
evolution," said John Climaco. "I look forward to bringing my industry
experience and operational perspective to help maximize the unique
opportunities that PDI has both envisioned and begun to execute."

About PDI, Inc.
PDI is a leading health care commercialization company providing superior
insight-driven, integrated multi-channel message delivery to established and
emerging health care companies. The company is dedicated to enhancing
engagement with health care practitioners and optimizing commercial
investments for its clients by providing strategic flexibility, full product
commercialization services, innovative multi-channel promotional solutions,
and sales and marketing expertise.

Through its Interpace Diagnostics subsidiary, PDI will commercialize
CardioPredict™, a molecular test panel shown to be important for predicting
how individual patients may respond to cardiovascular drugs such as
anticoagulants (blood thinners), statins (cholesterol-lowering drugs),
antiarrhythmics and beta-blockers. The company is also working to develop and
commercialize additional molecular diagnostic tests. For more information,
please visit the company's website at http://www.pdi-inc.com.

Forward-Looking Statements
This press release contains forward-looking statements regarding future events
and financial performance. These statements are based on current expectations
and assumptions involving judgments about, among other things, future
economic, competitive and market conditions and future business decisions, all
of which are difficult or impossible to predict accurately and many of which
are beyond PDI's control. These statements also involve known and unknown
risks, uncertainties and other factors that may cause PDI's actual results to
be materially different from those expressed or implied by any forward-looking
statement. For example, with respect to statements regarding projections of
future revenues, growth and profitability, estimated gross profit and
anticipated internal rate of return on investments actual results may differ
materially from those set forth in this release based on the loss, early
termination or significant reduction of any of our existing service contracts,
the failure to meet performance goals in PDI's incentive-based arrangements
with customers, the inability to secure additional business or our inability
to develop more predictable, higher margin business through in-licensing or
other means. Additionally, all forward-looking statements are subject to the
risk factors detailed from time to time in PDI's periodic filings with the
Securities and Exchange Commission, including without limitation, PDI's
previously filed Annual Report on Form 10-K for the year ended December 31,
2012 and current reports on Forms 10-Q and Forms 8-K. Because of these and
other risks, uncertainties and assumptions, undue reliance should not be
placed on these forward-looking statements. In addition, these statements
speak only as of the date of this press release and, except as may be required
by law, PDI undertakes no obligation to revise or update publicly any
forward-looking statements for any reason.

ScoliScore is a trademark of Axial Biotech, Inc.

SOURCE PDI, Inc.

Website: http://www.pdi-inc.com
Contact: INVESTOR CONTACT: Melody Carey, Rx Communications Group, LLC, (917)
322-2571, mcarey@rxir.com; or MEDIA CONTACT: Caren Begun, Green Room
Communications, (201) 396-8551, caren@greenroompr.com
 
Press spacebar to pause and continue. Press esc to stop.